HSP90AB1 and cancer: Ultimately, both the changes in SIINFEKL-loaded H2-Kb and IFN-γ production by OT1 cells indicated that Hsp90 inhibition in cancer cells can result in higher activation of tumour-specific CD8+ T cells.